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Summary
Background.— International guidelines recommend long-term use of evidence-based treatment
(EBT) combining beta-blockers, aspirin/clopidogrel, statins and either angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) after a myocardial infarction
(MI), to reduce cardiac morbidity and mortality.
Aims.— To evaluate medication adherence after hospital admission for MI and the relationship
with mortality and readmission for acute coronary syndrome.
Methods.— Observational, 30-month follow-up of patients admitted for acute MI in France in
the ﬁrst half of 2006 and still alive 6months later. Data from the national hospital discharge
database and the outpatient medications reimbursement database were linked for all patients
covered by the general health insurance scheme (70% of the French population). A patient was
considered as adherent when the proportion of days covered by a ﬁlled prescription was greater
than 80%.
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Results The proportion of nonadherent patients was 32.0% for beta-blockers, 24.0% for
statins, 22.7% for ACEIs/ARBs, 18.3% for aspirin/clopidogrel and 50.0% for combined EBT. Adher-
ence to EBT was decreased signiﬁcantly by age greater than 74 years, comorbidities and full
healthcare coverage for low earners. Prior EBT use and stent implantation, before or dur-
ing index hospitalization, increased adherence. After adjustment for patient characteristics
and management, prior use of each class decreased mortality. Nonadherence to EBT after MI
increased mortality and readmission (hazard ratio = 1.43, P < 0.0001).
Conclusion.— After MI, nonadherence to EBT is associated with a marked increase in all-cause
mortality and readmission for acute coronary syndrome. Cost-effective strategies for adherence
improvement should be developed among patient groups with poor adherence.
© 2010 Elsevier Masson SAS. All rights reserved.
MOTS CLÉS
Infarctus du
myocarde ;
Traitement ;
Adhérence ;
Réadmission ;
Décès
Résumé
Introduction.— Après un infarctus du myocarde (IM), l’association bêtabloquant, statine, anti-
agrégant plaquettaire (AP) et inhibiteur du système rénine-angiotensine ou un antagoniste
(IEC/ARA) est recommandée pour réduire la mortalité et la morbidité cardiaque.
Objectif.— Évaluer l’adhérence à cette prévention après une hospitalisation pour IM et son
impact sur la mortalité et les réadmissions pour un syndrome coronarien aigu (SCA).
Méthodes.— Les malades hospitalisés au cours du premier semestre 2006 et toujours vivants six
mois après ont été suivis pendant 30mois. Pour ceux couverts par le régime général, les données
de la base nationale des hospitalisations (PMSI) ont été reliées à celle des remboursements. Un
malade a été considéré comme adhérent lorsque la proportion de jours de traitement remboursé
rapporté aux 30mois de suivi était supérieure à 80%.
Résultats.— La proportion de non adhérents était de 32% pour les bêtabloquants, 24 % pour les
statines, 22,7 % pour les IEC/ARA, 18,3 % pour les AP et 50,0 % pour leur association. La propor-
tion d’adhérents à la quadrithérapie diminuait signiﬁcativement après 74 ans, avec l’existence
de comorbidités et d’une CMUC. Son utilisation avant l’hospitalisation et la pose d’un stent
améliorait l’adhérence. Après ajustement sur les caractéristiques et la prise en charge, la pres-
cription de l’association avant l’hospitalisation index diminuait la mortalité et la non adhérence
après l’IM l’augmentait (hazard ratio : 1,43, p < 0,0001).
Conclusion.— Après un IM, le manque d’adhérence est associé à une augmentation de la mor-
talité et des réadmissions pour SCA en France. Des actions coût-efﬁcaces pour améliorer
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bbreviations
CEI angiotensin-converting enzyme inhibitor
CS acute coronary syndrome
RB angiotensin receptor blocker
I conﬁdence interval
BT evidence-based treatment
TD long-term disease
I myocardial infarction
MSI programme de médicalisation des systèmes
d’information
NIIRAM système national d’informations inter-régimes de
l’assurance maladie
ackground
etween 1992 and 2002, the three French registers of acute
oronary syndromes, obtained from the Multinational moni-
oring of trends and determinants in cardiovascular disease
MONICA) Project, observed an overall reduction in mortal-
ty (particularly hospital mortality), but not in the incidence
f coronary disease. This can be explained partly by the
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ncrease and improvement in recommended invasive and
oninvasive treatments, as in other countries [1—3]. In
007, the French National Authority for Health published
uidelines for coronary disease management. As in many
nternational recommendations on secondary prevention for
atients with a myocardial infarction (MI), evidence-based
reatment (EBT) combining beta-blockers, statins, aspirin
nd/or clopidogrel, and angiotensin-converting enzyme
nhibitors (ACEIs) is recommended in France [4]. These rec-
mmendations are based on the results of clinical trials or
egistries that observed decreased rates of cardiovascular
eath and serious cardiac events, as well as an advantageous
ost-effectiveness ratio, for each medication class and their
ombination [5].
‘Real-world’ studies in North America and Europe have
bserved a temporal increase in use of EBT. For France,
ur previous study among 11,671 patients hospitalized for
I during the ﬁrst semester of 2006 reported a globally
atisfactory use of EBT in the 6months after discharge:
2% of patients were reimbursed for beta-blockers, 92%
or antiplatelets, 85% for statins, 80% for ACEIs/angiotensin
eceptor blockers (ARBs) and 62% for all four classes [6].
owever, several characteristics were associated with lower
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rates of prescription and refund of EBT (e.g. older age,
female sex, presence of comorbid conditions or associated
treatments, lower level of healthcare coverage, manage-
ment at non-university hospitals, lack of follow-up by a
cardiologist, or coronary artery bypass surgery, geographi-
cal region) [6—14]. Beyond initial EBT prescription after MI,
long-term adherence to treatment is known to play a crucial
role in survival improvement. Nevertheless, few ‘real-world’
results have been reported regarding the impact on mor-
tality of each class and on the EBT combination after MI
[15,16].
The objectives of this second study were to evaluate the
level of long-term adherence to EBT, as well as the factors
correlated with each medication class, and its impact on
survival after hospitalization for MI in France.
Methods
Sources of data
In France, the general health insurance scheme covers
70% of the population (i.e. 48million people in 2006) and
its information system (système national d’informations
inter-régimes de l’assurance maladie [SNIIRAM]) contains
individualized, anonymous and exhaustive data on all
health-spending reimbursements. Further information is
recorded, such as full refund for people with one of 30
long-term diseases (LTDs), including heart disease, and the
existence of full healthcare coverage for low earners (below
an income ceiling of D 7500 per year). Moreover, vital sta-
tus (all-cause mortality) stemming from the French National
Institute of Statistics and Economic Studies is available in the
SNIIRAM system. This information can be linked to the French
hospital discharge database (programme de médicalisation
des systèmes d’information [PMSI]), which provides medi-
cal information for all patients discharged from both private
and public hospitals, including the World Health Organiza-
tion International Statistical Classiﬁcation of Diseases and
Related Health Problems 10th Revision (ICD-10) diagnostic
codes.
Patient population
All hospitalizations from January to June 2006 with a
diagnosis-related group of MI were selected from the PMSI
data on short-term hospital stays. We selected all patients
covered by the general health insurance scheme. For each
patient, the ﬁrst hospital admission for MI in the ﬁrst half
of 2006 was considered as the index hospital admission.
These data were linked, using a common, anonymous patient
number, to the corresponding records in the reimburse-
ment database. Patients who died or were lost to follow-up
during the ﬁrst 6months were excluded from the analysis,
because their adherence behaviour could not be determined
accurately. Possible reasons for loss to follow-up included a
move abroad and a change in social security number (e.g.
for widowed women). If a patient was lost to follow-up
beyond 6months, they were included in the analysis as
a censored observation, with the date of the last refund
as the censoring point. All patients were followed for up
to 30months. For each EBT class (beta-blockers, statins,
s
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CEIs/ARBs, aspirin/clopidogrel), the analysis included all
atients who had at least one refund for this medication
lass after index admission. For the medication combina-
ion, all patients with at least one refund for each class
ere included.
ariables studied
or each index hospital admission, the following data were
ollected: sex, age, use of angioplasty, stent implantation,
nd coronary artery bypass graft procedures during the
ndex hospital admission or within 30 days after discharge,
ccording to the classiﬁcation of medical procedures used
n France. Prior hospitalization for cardiovascular events
coronary artery disease [acute MI, angina pectoris, coro-
ary atherosclerosis], coronary bypass surgery and stent
mplantation procedures) were identiﬁed using a speciﬁc
iagnosis-related group notiﬁed for hospital stays in the
months preceding index hospital admission. The presence
f a cardiovascular LTD 6months prior to index hospital
dmission and full healthcare coverage for low earners were
lso recorded.
Comorbid conditions were sought and deﬁned in several
ays, taking into account the entire period between 2005
nd 2008. Patients with depression or Parkinson’s disease
ere identiﬁed through reimbursements of speciﬁc medica-
ions by the presence of two dispensations at most, within
6-month interval. Diabetes and pulmonary diseases were
haracterized by the reimbursement of indicator medica-
ions at least twice over one calendar year. Inﬂammatory
ymptoms were identiﬁed by regular reimbursements of
teroidal or non-steroidal anti-inﬂammatory drugs (i.e. the
roportion of days covered by a ﬁlled prescription greater
han 80% in the 30-month follow-up period). For psychiatric
isorders and chronic liver disease, the occurrences of spe-
iﬁc LTDs were used. For neoplasia, the following indicators
ere used: radiotherapy or chemotherapy sessions, hospital
dmission with a main diagnosis of cancer, or a speciﬁc can-
er LTD beginning in 2004 or later. Alzheimer’s disease was
eﬁned by the speciﬁc LTD or by reimbursements of speciﬁc
edications issued at least twice within one calendar year
r by hospital admission with a speciﬁc dementia diagnosis-
elated group. For chronic renal disease, patients with a
chronic renal’ LTD and/or treated with dialysis and/or with
mmunosuppressive drugs were selected.
For each EBT class, drug adherence was assessed by a
edication possession ratio during the 30-month follow-up
eriod after hospitalization for MI, i.e. between the day
fter index hospital discharge and the last day of presence in
he study (end of follow-up or lost to follow-up). More specif-
cally, we used two different measures depending on the
edication class. For beta-blockers, statins and ACEIs/ARBs,
e calculated the proportion of days on which a patient
ad pills available (considering one pill per day as neces-
ary). For aspirin/clopidogrel, where combined treatment
s not unusual, adherence was measured by the ratio of the
umber of dates of supply to the number of months in the
tudy. For each medication class, patients were classiﬁed
n two groups: adherent patients (adherence measure > 80%)
nd nonadherent patients (otherwise). A patient was consid-
red to be adherent to the combined treatment if they were
dherent to each of the four medication classes. Moreover,
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onsumption during the 6months before the index hospital
dmission was considered to be ‘regular’ after at least three
edication refunds. Health outcome was assessed as death
r hospital readmission for acute coronary syndrome (ACS)
ithin the follow-up period.
tatistical analysis
or each recommended class of medication, as well as for
heir combined use, we compared adherent and nonad-
erent patients according to their baseline characteristics,
n-hospital management and use of concomitant medica-
ions after index hospital admission, by calculating the
roportions of nonadherent patients for each characteris-
ic and the crude odds ratios (adherent versus nonadherent
atients). To explore the crude relationship between age
nd adherence in more detail, we used locally-weighted
inear regression, highlighting non-linear trends graphically.
djusted odds ratios were determined using multivariable
ogistic regression models as a function of age, sex, full
ealthcare coverage for low earners, comorbidities, prior
ospitalization for cardiovascular condition, ‘cardiovascu-
ar’ LTD, use of the considered medication class in the
months before index admission, myocardial revascular-
zation procedures during and 1month after the index
dmission, deliveries and adherence to the other medication
lasses.
For each medication class, crude ACS-free survival rates
n adherent and in nonadherent patients were calculated
sing the Kaplan-Meier method. For further comparisons,
azard ratios were derived from Cox proportional haz-
rds models, both univariate and multivariable (using the
bove-mentioned characteristics as covariates). In addition,
djusted ACS-free survival rates were calculated with their
5% conﬁdence interval (CI) [17].
A P-value less than 0.05 was considered signiﬁcant. All
nalyses were performed using SAS software (SAS version
.1.3, SAS Inc., Cary, NC, USA).
esults
n the ﬁrst half of 2006, there were 24,075 hospital stays
ith a diagnosis-related group of MI in France. The anony-
ous patient number used for matching was missing for
701 (7.1%) of these patients and, of the 22,374 remain-
ng, only 14,788 (66.1%) admissions involved 14,007 patients
overed by the general health insurance scheme. Of these,
418 (10.1%) patients died during the index hospital admis-
ion, 769 (5.5%) died in the 6months after discharge and
16 (1.5%) were lost to follow-up within 6months. So,
1,604 patients were still present after 6months, and within
he 30-month follow-up period, 10,501 (90.5%) had at least
ne refund for statins, 9937 (85.6%) for beta-blockers, 9823
84.7%) for ACEIs/ARBs and 11,056 (95.3%) for aspirin or
lopidogrel. A total of 8249 (71.1%) patients had refunds
or all four medication classes.eterminants of adherence
he proportions of patients with an insufﬁcient adherence
easure (< 80% during the observation period) were 32.0%
f
t
b
c
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or beta-blockers, 24.0% for statins, 22.7% for ACEIs/ARBs,
8.3% for aspirin/clopidogrel and 50.0% for combined EBT.
ables 1 and 2 show the relationships between drug adher-
nce and patient characteristics. After adjustment for these
atient characteristics, adherence to EBT was found to be
ecreased signiﬁcantly by the following factors: age greater
han 74 years; comorbidities (neoplasia, renal disease,
hronic obstructive pulmonary disease, Alzheimer’s disease,
arkinson’s disease and depression); and full healthcare cov-
rage for low earners. Conversely, prior combination refund
nd stent implantation before or during index hospitaliza-
ion increased adherence. For each separate medication
lass, adherence was associated positively with adherence
o the three other classes as well as with prior use of
he medication class under consideration. Moreover, adher-
nce to beta-blockers was decreased in patients with renal
isease, chronic obstructive pulmonary disease or depres-
ion. Adherence to statins was decreased by presence of
iabetes mellitus, Alzheimer’s disease, depression or full
efund for cardiovascular disease. For ACEIs/ARBs, adher-
nce was decreased by renal disease or depression.
Fig. 1 illustrates the unadjusted relationship between
ge and medication adherence. For all medication classes,
nverse U-shaped curves were found, with the highest
dherence rates between 55 and 75 years. Note that an
ge younger than 45 years remained negatively related to
dherence after adjustment, but was signiﬁcant only for
spirin/clopidogrel.
ortality and rehospitalization for acute
oronary syndrome
or each medication class, as well as for combined EBT,
he unadjusted rates of mortality and readmission for ACS
fter the 30-month follow-up period were signiﬁcantly lower
n adherent patients, as illustrated in Fig. 2. After direct
djustment for patient characteristics, the differences
n ACS-free survival between adherent and nonadherent
atients became smaller, but remained signiﬁcant, except
or beta-blockers. For statins, adjusted rates of death or
CS readmission were 13.1% (95% CI 11.8—14.3) in nonadher-
nt patients and 8.1% (7.5—8.7) in adherent patients. The
djusted risks were, respectively, 9.5% (8.6—10.4) and 10.3%
9.6—11.0) for beta-blockers, 13.1% (11.8—14.3) and 10.4%
9.7—11.0) for ACEIs/ARBs, 12.6% (11.4—13.9) and 10.5%
9.9—11.2) for aspirin/clopidogrel, and 9.9% (9.1—10.8) and
.7% (5.9—7.5) for combined EBT.
Table 3 contains the hazard ratios obtained from multi-
ariable Cox models, adjusting for patient characteristics. In
greement with the adjusted rates of mortality or ACS read-
ission, the adjusted hazard ratios of nonadherence were
igniﬁcantly greater than 1 for all medication classes, except
or beta-blockers. For example, the adjusted hazard ratio
f nonadherence to statins was 1.58 (95% CI 1.37—1.81).
n addition, medication use before index admission for MI
ecreased mortality and readmission for ACS signiﬁcantly
or each medication class, but not for combined EBT. Note
hat only a small number of patients were treated with com-
ined EBT before index admission (7.3% of the 8249 users of
ombined EBT after MI). By comparison, 26.1% of the 10,501
tatin users had been treated with statins previously. More-
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Table 1 Univariate analysis of factors associated with adherence to evidence-based treatment in the 30-month follow-up period after hospitalization for myocardial
infarction in France.
Beta-blockers
(n = 9937)
Statins
(n = 10,501)
ACEIs/ARBs
(n = 9823)
Aspirin/clopidogrel
(n = 1056)
Combination
(n = 8249)
Nonadherent
(%)
ORa Nonadherent
(%)
ORa Nonadherent
(%)
ORa Nonadherent
(%)
ORa Nonadherent
(%)
ORa
Total 32.0 24.0 22.7 18.3 50.0
Age (years)
≤ 44 37.9 0.70e 29.0 0.60e 26.7 0.64e 24.3 0.51e 52.4 0.85b
45—54 33.1 0.86b 23.9 0.77d 23.4 0.76d 17.7 0.76d 47.7 1.02
55—64 29.2 1.03 18.5 1.08 19.4 0.96 13.2 1.08 45.4 1.12
65—74 29.9 1 19.6 1 18.8 1 14.1 1 48.3 1
75—84 30.7 0.96 27.7 0.64e 24.6 0.71e 21.2 0.61e 55.6 0.74e
≥ 85 40.3 0.63e 42.6 0.33e 33.3 0.46e 30.9 0.37e 67.1 0.46e
Sex
Female 31.7 1 27.4 1 25.5 1 22.2 1 53.3 1
Male 32.1 0.98 22.6 1.29e 21.6 1.24e 16.7 1.42e 48.9 1.19d
Full healthcare coverage for low earners
No 31.7 1 23.0 1 22.1 1 17.5 1 49.6 1
Yes 35.5 0.85 37.7 0.49e 33.4 0.56e 30.6 0.48e 55.9 0.78c
Comorbidities
Neoplasia 32.5 0.98 26.9 0.84b 25.8 0.83a 20.7 0.84b 54.8 0.81b
Diabetes mellitus 29.0 1.20d 25.2 0.91 21.8 1.08 17.1 1.12 48.7 1.07
Renal disease 43.0 0.62c 36.6 0.54d 45.5 0.35e 20.7 0.86 67.3 0.48d
COPD 36.3 0.80d 25.4 0.91 23.0 0.98 17.7 1.05 57.9 0.70e
Alzheimer’s disease 39.7 0.71b 41.6 0.43e 30.4 0.67c 31.9 0.47e 67.6 0.47e
Parkinson’s disease 38.2 0.76 36.0 0.56c 30.5 0.67 25.6 0.65b 62.9 0.59b
Depression 34.8 0.84d 28.0 0.76e 26.4 0.77e 20.2 0.85c 54.9 0.78e
Steroidal or non-steroidal anti-inﬂammatory use 29.0 1.15 21.2 1.18 26.3 0.82 14.5 1.33 55.5 0.80
Chronic hepatic disease 33.3 0.94 33.3 0.63 33.3 0.59 36.1 0.39d 64.3 0.55
Psychotic disorder 36.0 0.83 31.9 0.67c 30.6 0.66c 24.1 0.70b 56.7 0.76
Six months prior to index admission
Cardiovascular disease LTD 29.2 1.18c 27.9 0.77e 23.2 0.97 20.5 0.83c 51.1 0.95
Prior admission for cardiovascular reason
None 32.1 1 23.4 1 22.5 1 18.1 1 49.8 1
Stent implantation 23.1 1.58c 17.6 1.43b 18.3 1.29 12.7 1.52b 40.5 1.46c
Other diagnoses 33.8 0.92 32.6 0.63e 27.7 0.75d 22.7 0.75c 56.7 0.76c
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Table 1 (Suite )
Beta-blockers
(n = 9937)
Statins
(n = 10,501)
ACEIs/ARBs
(n = 9823)
Aspirin/clopidogrel
(n = 1056)
Combination
(n = 8249)
Nonadherent
(%)
ORa Nonadherent
(%)
ORa Nonadherent
(%)
ORa Nonadherent
(%)
ORa Nonadherent
(%)
ORa
Prior use of medications
Beta-blockers 22.9 1.83e - - - 45.8 -
Statins - 17.9 1.61e - - 44.6 -
ACEIs/ARBs - - 17.4 1.65e - 47.0 -
Aspirin/clopidogrel - - - 16.1 1.22d 49.3 -
Combination - - - - 39.0 1.62e
Index admission for MI
No procedures 34.7 1 31.9 1 28.7 1 28.4 1 57.8 1
Coronary artery bypass graft 29.2 1.29 14.9 2.67e 24.3 1.25 16.9 1.95d 52.2 1.25
Angioplasty without stent implantation 28.7 1.32 22.0 1.66d 21.6 1.46b 17.2 1.91e 48.2 1.47c
Stent implantation 31.1 1.17d 21.3 1.73e 20.2 1.59e 14.1 2.41e 47.5 1.51e
Concomitant medication use after index admission
Beta-blockers
No use - 33.8 0.33e 28.4 0.43e 29.4 0.24e - -
Nonadherent use - 41.3 0.24e 38.6 0.27e 33.5 0.20e - -
Adherent use - 14.4 1 14.7 1 9.0 1 - -
Statins
No use 45.9 0.37e - 37.8 0.26e 39.8 0.11e - -
Nonadherent use 56.5 0.24e - 48.6 0.17e 49.1 0.07e - -
Adherent use 23.7 1 - 13.8 1 6.7 1 - -
ACEIs/ARBs
No use 40.8 0.46e 31.1 0.39e - 25.2 0.33e - -
Nonadherent use 53.9 0.27e 51.2 0.17e - 42.9 0.15e - -
Adherent use 24.2 1 15.1 1 - 9.9 1 - -
Aspirin/clopidogrel
No use 40.8 0.49e 37.0 0.29e 40.5 0.27e - - -
Nonadherent use 63.4 0.20e 69.5 0.07e 55.5 0.15e - - -
Adherent use 25.4 1 14.5 1 15.4 1 - - -
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; COPD: chronic obstructive pulmonary disease; LTD: long-term disease; MI: myocardial infarction; OR:
odds ratio.
a Adherent vs nonadherent medication users.
b p < 0.05.
c p < 0.01.
d p < 0.001.
e p < 0.0001.
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Table 2 Multivariable analysis of factors associated with adherence to evidence-based treatment in the 30-month follow-
up period after hospitalization for myocardial infarction in France.
Beta-blockers Statins ACEIs/ARBs Aspirin/clopidogrel Combination
ORa ORa ORa ORa ORa
Age (years)
≤ 44 0.97 0.85 0.97 0.74b 0.86
45—54 1.08 0.92 0.95 0.95 1.02
55—64 1.09 1.10 0.99 1.09 1.12
65—74 1 1 1 1 1
75—84 1.15 0.79c 0.90 0.84 0.81c
≥ 85 1.00 0.48e 0.82 1.09 0.56e
Male sex 0.89b 1.01 1.07 1.12 1.01
Full healthcare coverage for low
earners
1.30c 0.59 0.75c 0.58e 0.74c
Comorbidities
Neoplasia 1.09 0.88 0.90 0.86 0.84b
Diabetes mellitus 1.09 0.74e 0.99 1.09 1.08
Renal disease 0.63b 0.75 0.34e 1.64b 0.54c
COPD 0.73e 1.02 1.02 1.27c 0.72
Alzheimer’s disease 1.08 0.70b 1.02 0.80 0.62b
Parkinson’s disease 0.92 0.77 0.85 1.02 0.75
Depression 0.87b 0.86b 0.84c 1.16b 0.85c
Steroidal or non-steroidal
anti-inﬂammatory use
1.16 1.19 0.69b 1.33 0.82
Chronic hepatic disease 1.27 1.25 0.88 0.44b 0.64
Psychotic disorder 1.08 0.80 0.85 0.89 0.87
Six months prior to index admission
Cardiovascular disease LTD 1.06 0.68e 0.93 0.78c 0.94
Prior admission for cardiovascular
reason
Stent implantation 1.18 1.18 0.87 1.13 1.33b
Other diagnoses 0.94 0.68 e 0.83 0.94 0.78c
Prior use of medications
Beta-blockers 1.86e - - - -
Statins - 1.69e - - -
ACEIs/ARBs - - 2.00e - -
Aspirin/clopidogrel - - - 1.54e -
Combination - - - - 1.86e
Index admission for MI
No procedures 1 1 1 1 1
Coronary bypass graft 0.96 2.25d 0.80 1.04 1.11
Angioplasty without stent
implantation
1.04 1.17 1.09 1.28 1.34b
Stent implantation 0.91 1.15b 1.13 1.92e 1.42e
Concomitant medication use after
index admission
Beta-blockers
No use - 0.56e 0.74d 0.44e -
Nonadherent use - 0.42e 0.47e 0.37e -
Adherent use - 1 1 1 -
Statins
No use 0.51e - 0.47e 0.21e -
Nonadherent use 0.41e - 0.33e 0.13e -
Adherent use 1 - 1 1 -
ACEIs/ARBs
e e eNo use 0.62 0.5
Nonadherent use 0.47e 0.3
6 - 0.62 -
4e - 0.32e -
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Table 2 (Suite )
Beta-blockers Statins ACEIs/ARBs Aspirin/clopidogrel Combination
ORa ORa ORa ORa ORa
Adherent use 1 1 - 1 -
Aspirin/clopidogrel
No use 0.64c 0.49e 0.41e - -
Nonadherent use 0.36e 0.13e 0.30e - -
Adherent use 1 1 1 - -
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; COPD: chronic obstructive pulmonary disease; LTD:
long-term disease; MI: myocardial infarction; OR: odds ratio.
a Adherent vs nonadherent medication users, adjusted for other characteristics.
b p < 0.05.
c p < 0.01.
d p < 0.001.
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ie p < 0.0001.
ver, the ACS-free survival in users of each medication class
as signiﬁcantly related to concomitant use of the three
ther medication classes. With respect to their concomi-
ant medication use, patients were classiﬁed as ‘non-users’,
nonadherent users’ or ‘adherent users’ for each medication
lass. So, concomitant adherence with statins is signiﬁcantly
elated to ACS-free survival in the users of each of the other
edication classes. The same holds for concomitant adher-
nce to ACEIs/ARBs and to aspirin/clopidogrel. By contrast,
oncomitant adherence to beta-blockers is not signiﬁcantly
D
T
a
t
igure 1. Rates of adherence to evidence-based treatment in the 30-mo
n France, as a function of age.elated to ACS-free survival in the users of another med-
cation class, but non-use of beta-blockers is related to
CS-free survival.iscussion
his large, population-based, observational study on
dherence to EBT in the 30months after MI combined hospi-
alization and reimbursement data for patients. The study
nth follow-up period after hospitalization for myocardial infarction
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sFigure 2. Kaplan-Meier estimates of acute coronary syndrome-fr
30-month follow-up period after hospitalization for myocardial infa
documents lower adherence for older age, speciﬁc comor-
bid conditions and low income with full healthcare coverage,
and higher adherence for patients with stent implantation
and prior use of EBT. In addition, a strongly improved survival
rate was found in patients adherent to combined EBT, but
also, separately, in adherent users of statins, ACEIs/ARBs
and aspirin/clopidogrel. In contrast, adherence to beta-
blockers had no signiﬁcant relationship to survival after
adjustment.
AdherenceProportions of nonadherent patients reported by this study
are similar to those from other studies, with around
30% for beta-blockers and around 20% for statins and
ACEIs/ARBs [11,15,18]. Few data have been reported for
p
p
t
a
trvival according to adherence to evidence-based treatment in the
n in France.
spirin/clopidogrel (and consequently for the whole EBT
ombination) because aspirin is available over the counter
nd/or is not reimbursed in most countries. However, a study
ound that only 20% of the patients took the combination of
spirin, beta-blockers and statins consistently [19]. Another
tudy reported that 12% of patients discontinued this com-
ination 1month after discharge [20]. In France, aspirin is
vailable at a speciﬁc dosage for cardiovascular risk preven-
ion and each delivery is reimbursed. Consequently, our data
hould contain all aspirin deliveries of interest.
The reasons for underprescription range from absolute to
ossible relative contraindications (e.g. chronic obstructive
ulmonary disease and beta-blockers, as found in this study)
o reluctance to take additional medication in patients
lready receiving a number of non-cardiovascular drugs. In
heory, more than 95% of patients may be treated by statins,
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Table 3 Association of adherence to evidence-based treatment with mortality or readmission for acute coronary syndrome in the 30-month follow-up period after
hospitalization for myocardial infarction in France.
Beta-blockers Statins ACEIs/ARBs Aspirin/clopidogrel Combination
Crude HR Adjusted
HRa
Crude HR Adjusted
HRa
Crude HR Adjusted
HRa
Crude HR Adjusted
HRa
Crude HR Adjusted
HRa
Medication use after index
admission for MI
No adherence 1.22c 0.9 2.29e 1.58e 1.91e 1.32b 2.01e 1.19b 1.73e 1.43e
Adherence 1 1 1 1 1 1 1 1 1 -
Medication use in 6months prior
to index admission
Beta-blockers 1.90e 1.16b - - - - - - - -
Statins - - 1.60e 1.20c - - - - - -
ACEIs/ARBs - - - - 1.96e 1.25d - - - -
Aspirin/clopidogrel - - - - - - 2.33e 1.40e - -
Combination - - - - - - - - 1.91e 1.21
Concomitant medication use
after index admission for MI
Beta-blockers
No use - - 2.08e 1.23b 2.4e 1.20b 2.40e 1.23c - -
Nonadherent use - - 1.15b 0.9 1.27d 0.96 1.20c 0.91 - -
Adherent use - - 1 1 1 1 1 1 - -
Statins
No use 5.16e 1.97e - - 4.95e 1.76e 5.02e 1.92e - -
Nonadherent use 2.18e 1.54e - - 2.30e 1.58e 2.26e 1.60e - -
Adherent use 1 1 - - 1 1 1 1 - -
ACEIs/ARBs
No use 1.38d 0.99 1.17 0.94 - - 1.45e 1.02 - -
Nonadherent use 1.93e 1.32d 1.93e 1.38e - - 1.89e 1.30e - -
Adherent use 1 1 1 1 - - 1 1 - -
Aspirin/clopidogrel
No use 3.98e 1.59d 2.99e 1.28 3.53e 1.25 - - - -
Nonadherent use 2.07e 1.30 d 1.95e 1.22b 2.03e 1.16 - - - -
Adherent use 1 1 1 1 1 1 - - - -
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; HR: hazard ratio; MI: myocardial infarction.
a Further adjusted for age, sex, comorbidities, full healthcare coverage for low earners, prior hospitalization for cardiovascular reason, prior full healthcare coverage for heart disease,
myocardial revascularization procedures during index admission.
b p < 0.05.
c p < 0.01.
d p < 0.001.
e p < 0.0001.
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as true contraindications are rare. The same applies for
ACEIs/ARBs, whereas contraindications are more common
for beta-blockers. Furthermore, adverse reactions or intol-
erance are also likely to have an inﬂuence on medication
adherence. For example, we did not ﬁnd adherence differ-
ences between men and women, except for beta-blockers,
which could be explained by sexual side effects such as
impotence or loss of libido.
Older age is related to a lower use of preventive treat-
ments [9,15,21,22]. In our study, the fall in adherence to
combined EBT over the age of 75 years seems to be due
mainly to low adherence to statins. For both combined EBT
and statins, the negative effect of older age on adherence
remained signiﬁcant after adjustment for comorbidities and
myocardial revascularization procedures. Reasons for low
adherence range from possible contraindications to reluc-
tance to take additional medication in patients receiving
numerous non-cardiovascular drugs. At the other end of the
spectrum, the lower adherence to each class of secondary
prevention therapy in very young MI patients (< 45 years)
may appear surprising. However, this association did not
remain signiﬁcant after adjustment for sex, comorbidi-
ties and myocardial vascularization procedures, except for
aspirin/clopidogrel. One possible explanation could be that
occurrence of an MI among the youngest patients is linked
with more comorbidities and risk factor exposure, in asso-
ciation with poorer health management, and consequently,
with an increased risk of another MI; this has been pointed
out previously [23]. Also, younger, active patients might be
more reluctant to take lifelong secondary prevention medi-
cation. Finally, there was a higher proportion of low-income
patients in the younger population — a factor related to
poorer adherence to chronic medications; this might explain
why the impact of younger age on adherence was no longer
signiﬁcant after multivariable adjustment, including social
variables.
In a previous study on diabetic patients from the same
population, we found similar persistence rates after hos-
pitalization at 6months between diabetic patients (85.5%)
and non-diabetic patients (85.2%), adjusted for age and sex
[24]. During the 6months before their hospitalization for MI,
diabetic patients had statins more often than non-diabetic
patients (40.8% vs 19.9%, respectively), with adjustment for
age and sex. This could argue for large primary prevention
among diabetics. But in this study, diabetic patients had
30months of adherence, similar to non-diabetics, except for
statins, despite being at higher risk of an ischaemic event.
This could suggest more frequent secondary or adverse
effects speciﬁc to diabetic patients, with more frequent
interruption.
Others comorbidities were related to lower adherence,
such as patients with chronic renal disease, who had a
signiﬁcantly lower adherence rate for combined EBT and
speciﬁcally for beta-blockers and ACEIs/ARBs, as reported in
another study in patients undergoing dialysis [25]. Low EBT
adherence rates in patients with severe comorbidities may
be explained by consideration of the substantial risk of dying
irrespective of the coronary artery disease, such as for neo-
plasia, Alzheimer’s disease and Parkinson’s disease. There
is no question that prescribing secondary prevention medi-
cations in patients with severe comorbidities may represent
a true ethical issue for prescribers, discussion of which is
s
a
M
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eyond the scope of the present study. Lastly, the associa-
ion between the use of antidepressant medications and low
dherence should be noted, because it involved about 20%
f our population [6].
The positive effect of ﬁnancial reimbursement on pre-
ention or care consumption has already been documented
idely. In our earlier study [6], we observed that low
arners with full healthcare coverage had similar levels of
ombined EBT persistence at 6months. But, their adher-
nce at 30months was no longer similar; it was lower for
ach medication class, except for beta-blockers, even after
djustment for some comorbidities and myocardial revas-
ularization procedures. In theory, in France, low earners
ave free access to inpatient and outpatient care. Low
dherence could be explained by a lack of adjustment for
omorbidities, because these patients had a wide range of
omorbidities, with high hospitalization rates [26].
Nevertheless, true contraindications are rare for statins
nd ACEI/ARBs, whereas they are more common for
spirin/clopidogrel. This is also the case for beta-blockers,
o which low earners had higher adherence. This could
eﬂect clinicians’ attitudes to patients who are receiv-
ng many medications, preferring to reserve beta-blocker
onotherapy for individuals with more cardiovascular risks,
uch as hypertension.
EBT was used more often in patients who underwent
yocardial revascularization, mainly by stent implantation,
rior to or after the index hospitalization, as noted pre-
iously at 6months [27]. For each medication class, as
ell as for combined EBT, patients with medication use
efore index admission were more often adherent after MI.
onadherence to a given medication class was related to
onadherence to the other medication classes, a ﬁnding that
as also been reported previously [11].
ortality
linical trials have demonstrated the positive effects of EBT
n survival after MI. In our study, adherence was related
o a 38% reduction in all-cause mortality and ACS read-
ission rate at 30months for statins, a 21% reduction for
CEIs/ARBs and a 16% reduction for aspirin/clopidogrel.
ith regard to statins, the reduction is higher than that
eported by clinical trials (around 20%) [28]. One hypoth-
sis is that observational studies are conducted mainly in
n unselected population, reﬂecting the overall beneﬁts of
tatins. Prior statin use was also related to improved clinical
utcome, but this effect disappears with early withdrawal
29].
In this study, adherence to beta-blockers was not signiﬁ-
antly related to ACS-free survival. The incremental survival
eneﬁts associated with beta-blocker use are under debate,
ith the use of reperfusion therapies and new drugs added
o the EBT combination. This debate focuses more specif-
cally on the true beneﬁt of beta-blockers in people who
ave sustained an AMI at low risk, with complete reperfu-
ion and preserved left ventricular function. Unfortunately,
peciﬁc clinical and disease severity data were not avail-
ble in our study. A similar study that included elderly
I survivors found no effect of intermediate adherence
o beta-blockers (40—79%) compared with high adherence
≥ 80%) and a signiﬁcant effect for low adherence (< 40%)
3b
a
N
c
i
q
n
f
r
t
B
m
r
M
S
T
t
d
a
i
d
i
l
h
d
m
d
a
v
I
c
t
h
b
i
s
I
c
o
t
b
i
f
o
d
n
t
e
c
t
c
c
a
a
w
r
b
o
t
b
o
d
b
C
T
e
t
r
p
E
e
p
C
N
R
[74
ut with a weak magnitude [12]. This last study also found
signiﬁcant positive effect for prior use of beta-blockers.
evertheless, lack of beta-blocker use after MI is asso-
iated with low survival. This could be explained by an
ndication bias, with more severe clinical status or fre-
uent limitations and contraindications for patients with
o beta-blocker refunds. We tried to minimize this con-
ounding effect by including patients with at least one
efund in each medication group after MI. Nevertheless,
hose with few refunds may have a different clinical status.
eta-blocker beneﬁt could be time-dependent, with marked
id-term and long-term effects. A study by Huikuri et al.
eported that sudden death only occurred 20months after
I [30].
trengths and limitations
he strength and originality of this study are derived from
he cross-linkage of various large medico-administrative
atabases, thereby providing comprehensive hospitalization
nd medical consumption data. Because the general health
nsurance scheme covers 70% of the French population, our
ata are likely to be fairly representative of the level of care
n France in 2006, although we cannot exclude that popu-
ations covered by other health insurance schemes might
ave been treated differently. Access to reimbursement
atabases allowed us to perform adjustment for conco-
itant non-cardiovascular diseases. The reimbursement
atabase is comprehensive for all medications purchased
nd reimbursed; in contrast with telephone or mail sur-
eys, there is no recall bias and a low non-responder rate.
t does not take into account self-medication, rare in this
ontext, nor the fact that some patients might buy medica-
ions and not consume them; actual use of the medications,
owever, is certainly more likely when medications have
een purchased repeatedly than when drug consumption
s accounted for on the sole basis of declaration of pre-
criptions by doctors or a fortiori patient self-declaration.
t should be noted that all MI patients can get full health
overage for their disease management. During acute care
r long-term hospitalization, as with public institutionaliza-
ion, medications are included in hospital costs without it
eing possible to identify them. For this reason, in part, we
ncluded patients 6months after their index hospitalization
or MI, but we may have underestimated adherence for the
ldest people in long-stay hospitals or public institutions for
ependent old people. Finally, the medico-administrative
ature of the databases does not permit adjustment for cer-
ain speciﬁc clinical factors, such as those specifying the
xtent or severity of the disease. Nevertheless, diagnosis of
omorbidities was strengthened by data on speciﬁc medica-
ion reimbursement and full coverage for these long-term
hronic diseases. Indication bias should be considered, with
haracteristics and clinical differences between those with
higher or lower (for long-term prevention) risk of death
ccording to clinical status and comorbidities. Thus, results
ere adjusted for patients’ characteristics and myocardial
evascularization procedures. Survivor treatment selection
ias and competing medical issues are unlikely to affect
ur results because the classical effect of each medica-
ion and adherence was apparent. Good adherence could
e a surrogate for other factors that reﬂect a high quality
[P. Tuppin et al.
f care, healthy behaviours or more effective treatment. A
ose effect for adherence was assessed by studies on beta-
lockers and statins [12].
onclusions
his study showed that 50% of patients had good adher-
nce to combined EBT 30months after MI. Good adherence
o EBT and combination treatment was associated with a
eduction in all-cause mortality and ACS admission among
atients. The survival and readmission beneﬁts of combined
BT and the factors found to be associated with adherence
mphasize the importance of promoting EBT among speciﬁc
opulation groups.
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